首页> 外文期刊>Perfusion >Off-pump versus on-pump revascularization in females: a meta-analysis of observational studies
【24h】

Off-pump versus on-pump revascularization in females: a meta-analysis of observational studies

机译:女性的无泵与无泵血运重建:一项观察性研究的荟萃分析

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Coronary revascularization in female patients presents several challenges, including smaller target vessels and smaller conduits. Furthermore, late presentation and more co-morbidities than males may increase complication rates. The aim of this study was to assess whether off-pump coronary artery bypass (OPCAB) improves outcomes when compared to on-pump coronary artery bypass (ONCAB) in the female population.Methods: A systematic literature review identified six observational studies, incorporating 233 13 patients (n=9596 OPCAB, 13717 ONCAB). These were meta-analyzed using random effects modeling. Heterogeneity, subgroup analysis, quality scoring and publication bias were assessed. The primary endpoints were 30-day mortality and major cardiac, respiratory and renal complications. Secondary endpoints were the number of grafts per patient. Results: No statistically significant difference was observed in 30-day mortality between the OPCAB and ONCAB groups (4.8% vs. 0.7%; OR 0.96; 95%CI [0.41, 2.24], p=0.92). Significant inter-study heterogeneity was also present (I2=94%) and was not explained by study size or quality. Peri-operative myocardial infarction (OR 0.65; 95%CI [0.51, 0.84], p=0.0009) was significantly lower with OPCAB without significant heterogeneity; however, OPCAB did not significantly alter other morbidity outcomes. OPCAB was associated with a trend towards fewer grafts per patient than ONCAB. Conclusions: OPCAB is a safe alternative to ONCAB in the surgical revascularisation of female patients and may reduce post-operative myocardial infarction (Ml). However, this does not translate into a reduction in 30-day mortality and OPCAB does not significantly improve other cardiovascular, renal or neurological outcomes. Late outcome data remains lacking and a well-structured, randomized trial is required to answer vital questions regarding the effect of OPCAB on women in the long-term.
机译:背景:女性患者的冠脉血运重建面临一些挑战,包括较小的靶血管和较小的导管。此外,较男性迟发和更多的合并症可能增加并发症发生率。这项研究的目的是评估女性人群中非体外循环冠状动脉搭桥术(OPCAB)与非体外循环冠状动脉搭桥术(ONCAB)相比是否改善结果。方法:系统文献综述确定了六项观察性研究,纳入233 13位患者(n = 9596 OPCAB,13717 ONCAB)。使用随机效应模型进行荟萃分析。评估了异质性,亚组分析,质量评分和出版物偏倚。主要终点为30天死亡率以及主要的心脏,呼吸和肾脏并发症。次要终点是每位患者的移植物数量。结果:OPCAB组和ONCAB组之间30天死亡率没有统计学差异(4.8%比0.7%; OR 0.96; 95%CI [0.41、2.24],p = 0.92)。研究间的异质性也很显着(I2 = 94%),并且没有用研究规模或质量来解释。 OPCAB围手术期心肌梗死(OR 0.65; 95%CI [0.51,0.84],p = 0.0009)显着降低,且无明显异质性。但是,OPCAB并未显着改变其他发病率结果。 OPCAB与每名患者比ONCAB移植物减少的趋势有关。结论:在女性患者的手术血运重建中,OPCAB是ONCAB的安全替代品,可减少术后心肌梗塞(M1)。但是,这并不意味着30天死亡率的降低,OPCAB不能显着改善其他心血管,肾脏或神经系统的预后。仍然缺乏后期结果数据,因此需要一项结构合理的随机试验来回答有关OPCAB长期影响妇女的重要问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号